Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald J Buchsbaum

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
Gynecologic Oncology Reports|April 6, 2017
Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewHaller J Smith, J Michael Straughn, Donald J Buchsbaum, et al.
Molecular Cancer Therapeutics|March 17, 2007
High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenograftsHyunki Kim, Tandra R Chaudhuri, Donald J Buchsbaum, et al.
Gynecologic Oncology|October 16, 2013
The Wnt/β-catenin pathway in ovarian cancer: a reviewRebecca C Arend, Angelina I Londoño-Joshi, J Michael Straughn, et al.
Oncology Reviews|June 7, 2017
Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-OncologyGeorge E Naoum, Donald J Buchsbaum, Fady Tawadros, et al.
World Journal of Stem Cells|September 27, 2014
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?Christen L Walters Haygood, Rebecca C Arend, J Michael Straughn, et al.
Cancer Biology & Therapy|January 26, 2011
Combined modality therapy with TRAIL or agonistic death receptor antibodiesHope M Amm, Patsy G Oliver, Choo Hyung Lee, et al.
ORL; Journal for Oto-Rhino-Laryngology and Its Related Specialties|October 22, 2008
In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenograftsJoni B Skipper, Lacey R McNally, Eben L Rosenthal, et al.
American Journal of Surgery|August 23, 2008
Molecular targeted therapies for pancreatic cancerDaniel Borja-Cacho, Eric Hans Jensen, Ashok Kumar Saluja, et al.
Journal of Cellular Biochemistry|January 17, 2017
Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer CellsRomone M Fancy, Harrison Kim, Tong Zhou, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|November 23, 2006
Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivoLeo Christopher DeRosier, Zhi-Qiang Huang, Jeffrey C Sellers, et al.
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
Gynecologic Oncology Reports|April 6, 2017
Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewHaller J Smith, J Michael Straughn, Donald J Buchsbaum, et al.
Molecular Cancer Therapeutics|March 17, 2007
High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenograftsHyunki Kim, Tandra R Chaudhuri, Donald J Buchsbaum, et al.
Gynecologic Oncology|October 16, 2013
The Wnt/β-catenin pathway in ovarian cancer: a reviewRebecca C Arend, Angelina I Londoño-Joshi, J Michael Straughn, et al.
Oncology Reviews|June 7, 2017
Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-OncologyGeorge E Naoum, Donald J Buchsbaum, Fady Tawadros, et al.
World Journal of Stem Cells|September 27, 2014
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?Christen L Walters Haygood, Rebecca C Arend, J Michael Straughn, et al.
Cancer Biology & Therapy|January 26, 2011
Combined modality therapy with TRAIL or agonistic death receptor antibodiesHope M Amm, Patsy G Oliver, Choo Hyung Lee, et al.
ORL; Journal for Oto-Rhino-Laryngology and Its Related Specialties|October 22, 2008
In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenograftsJoni B Skipper, Lacey R McNally, Eben L Rosenthal, et al.
American Journal of Surgery|August 23, 2008
Molecular targeted therapies for pancreatic cancerDaniel Borja-Cacho, Eric Hans Jensen, Ashok Kumar Saluja, et al.
Journal of Cellular Biochemistry|January 17, 2017
Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer CellsRomone M Fancy, Harrison Kim, Tong Zhou, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|November 23, 2006
Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivoLeo Christopher DeRosier, Zhi-Qiang Huang, Jeffrey C Sellers, et al.
Pageof 16